$34.00
Manufacturer: Ukraine
Growth failure due to insufficient secretion of growth hormone.
Description
Somatin (somatropin) lyophilisate for solution for injections 1.3 mg. (4 IU) №1 vial
Composition
active ingredient: somatropin;
1 bottle of the drug contains recombinant human somatropin 1.3 mg (4 IU) or 2.6 mg (8 IU);
excipients: mannitol, glycine, sodium dihydrogen phosphate, disodium phosphate;
solvent: metacresol, water for injection.
Dosage form
Lyophilisate for solution for injection complete with solvent.
Basic physico-chemical properties: drug – white or almost white powder; The solvent is a clear, colorless or slightly yellowish liquid.
Pharmacotherapeutic group
Hormones of the anterior pituitary gland and their analogues. Somatropin and somatropin agonists. Somatropin.
ATX code H01A C01.
Pharmacological properties
This drug is included in a group of drugs that belong to a group of drugs based on hormones secreted by the anterior lobe of the pituitary gland – a gland from the category of endocrine glands, which is located at the base of the skull.
The drug consists of the human hormone somatropin (recombinant growth hormone) – a protein secreted by E. coli bacterial cells. Among the genes of these bacteria, there is one that contains the encoded growth rates of the organism.
Also, somatropin hormone affects both the rate at which a person grows, but also his metabolism, including carbohydrate (causes an increase in blood glucose), body anatomy, homeostasis, learning. It mainly affects the growth of tubular bones located in the limbs.
It is especially effective when injected, reaching maximum values 4 hours after administration.
Indications
This drug Somatin is used to treat short stature in children with hypopituitarism (growth hormone deficiency) and Turner syndrome.
Contraindications
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
Contraindicated for the closure of the epiphyses (cessation of bone growth), oncological diseases. In children with chronic kidney disease before kidney transplantation, treatment with this drug should be discontinued.
Use with caution in diabetes mellitus (hypoglycemic attacks are possible), hypothyroidism, increased intracranial pressure, intracranial hypertension.
Application during pregnancy and lactation
This drug is contraindicated in the treatment of pregnant women.
If it is necessary to take the drug during breastfeeding, lactation is suspended.
Method of administration and dosage
The drug Somatin is administered by injection (subcutaneously and intramuscularly), under the constant supervision of an experienced physician with experience in diagnosing and treating patients with growth hormone deficiency.
The recommended weekly dose for growth hormone deficiency is from 0.6-0.7 IU / kg body weight to 1.0 IU / kg body weight.
The dosage is divided into 6 – 7 equal parts and is administered subcutaneously or intramuscularly in the evening.
In case of persistent edema or severe paresthesia, the dose of the drug is reduced to avoid the development of carpal tunnel syndrome. To prevent the development of lipoatrophy, the injection site must be changed.
Overdose
Overdose can cause a sharp decrease in blood insulin levels (hypoglycemia phenomenon). Then the sugar level rises sharply and hyperglycemia may develop.
With chronic overdose, gigantism or acromegaly may develop.
Other phenomena that occur with an excessive dose of growth hormone may also appear.
In case of overdose, treat the symptoms.
Side effects
The drug is usually well tolerated. Side effects may occur in the form of:
- hypersensitivity reactions;
- itching, redness may occur at the injection site;
- hypothyroidism.
In some cases, if the short stature is due to a deletion in the growth hormone gene complex, treatment with somatropin can cause the body to produce antibodies that inhibit the growth process.
In this case, epiphyseolysis may occur, accompanied by damage to the hip joint. A child with an unexplained lameness should be examined.
Recent Reviews